Abstract: As a kind of artificially synthesized somatostatin analogues containing eight amino acids, octreotide can specificially bind with somatostatin receptor (SSTR) which is usually over-expressed on many tumor cells. So it may have important clinic significance to use octreotide and their analogues labeled with positron radionuclides as the tumor probes for the diagnosis and treatment of SSTR positive tumor. This review provides a critical and thorough overview of the development of octreotide and their analogues labeled with positron emitting nuclides and the in vivo evaluation of PET radiopharmaceuticals that have emerged so far along with their possible applications in nuclear medicine.